HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. - Wikidata - wikimedia - TriplyDB

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

http://www.wikidata.org/entity/Q33963958

about

Antiretroviral therapy response among HIV-2 infected patients: a systematic review Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2 HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.Genetic Consequences of Antiviral Therapy on HIV-1.Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform.Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.Clinical validation of a novel diagnostic HIV-2 total nucleic acid qualitative assay using the Abbott m2000 platform: Implications for complementary HIV-2 nucleic acid testing for the CDC 4th generation HIV diagnostic testing algorithm.HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.Detection and differentiation of HIV-2 using the point-of-care Alere q HIV-1/2 Detect nucleic acid test.

P2860

Q27003854-7A7478EC-7338-4041-B31B-E137C67764C8 Q34428902-ECFA05EA-EF5B-4F88-B9A7-C76738B4EF98 Q35083423-2EFB994D-881E-4983-A07C-D77AF76DDE82 Q35134947-C04CCCC3-2303-486C-BD28-B6E6B957EE71 Q35773113-F8FC717E-7628-4D4A-BE3E-674E895C61C4 Q36239297-1FE48214-93CF-4B6A-AE4E-E75BF16C4D0B Q36839676-A77E2B79-7701-4953-9B75-CF2B816CAC08 Q37026564-E430A541-A586-4D44-ADDF-54E645EE060D Q38560855-226EF050-A43A-4FDA-A96F-6A8302D3F851 Q40413304-D8BCAFDF-7AED-425E-B3CE-77202A38048F Q41465991-65F98104-CCFF-434B-8258-F2EB0D1AB88F Q46590840-2D4E7CF4-E9FE-4319-80B3-C5C12A2AD976

P2860

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

http://www.wikidata.org/entity/Q33963958

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

@ast

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

@en

type

label

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

@ast

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

@en

prefLabel

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

@ast

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

@en

P1433

Q33963958-7E8BDA7F-43D4-42A5-B4F2-CB197AC5F136

P1476

Q33963958-7B9DBB98-1C0F-4391-A25E-3291FCD70BEF

P2093

Q33963958-1F468A82-1C9B-4CA5-95F5-CBA5C3B4B6EF

Q33963958-225D4575-07FA-45B9-B55F-96D2E98BCFDE

Q33963958-2448E710-247D-42A1-873F-93FC113A63A8

Q33963958-2D35B445-251D-49DB-868A-9AC9301D569E

Q33963958-2FFE98F9-39CF-4747-A927-61DD54325AFB

Q33963958-35354C0F-59AC-41BC-BEF1-1786C7DC45D2

Q33963958-40B5196E-0991-4692-8A9A-85E2E30CC1CC

Q33963958-522D88C6-3C9B-40E8-8663-7EC2981240C6

Q33963958-5524C628-9CA8-4DD2-81CA-4A5C75957666

Q33963958-5A96D492-A85E-4B31-921B-C84ADF1E4E77

P2860

Q33963958-16176C62-FC42-4127-BBA5-6686C9DB3B1B

Q33963958-2BA07366-4470-4651-BEFA-251968623675

Q33963958-2CC16D26-070A-4849-ADBB-2ACF776211CB

Q33963958-2F87F2DC-BE7F-460F-9558-F47CBB37254B

Q33963958-3A89BA0A-CFDC-435A-A187-50B46D1D9C5E

Q33963958-451374E9-CC29-42E1-847B-8926B160A37D

Q33963958-4E8BE2DC-2EAA-4A3E-818E-B62B4A26CA32

Q33963958-5848E96D-64E9-47CA-B147-3454D88AD433

Q33963958-5C98A2E5-90DC-4D79-8DBF-5CBCEFA52166

Q33963958-5F6C50F3-CAB5-4D55-9740-C0D98D9E1243

P304

Q33963958-87C2474E-5C6D-4E21-8A6B-02515F0410C6

P31

Q33963958-24D358CB-F864-439A-B3D3-7368CC185A7C

P356

Q33963958-718D47AB-AA03-47A2-ABD7-315BE9AB0A2D

P407

Q33963958-61566001-2FD8-4B6E-AEF4-423FA8D1DEE3

P433

Q33963958-DCED342B-62D0-4C78-9384-5867B1412204

P478

Q33963958-A1C7BE92-8B55-42C6-9E8B-C7A56099D484

P50

Q33963958-9D94742B-F3A3-452D-9DA0-517BFB761DD5

Q33963958-ADA43F81-E259-4D3C-A04E-24A55B8B68D6

P577

Q33963958-946A7BF6-BC3E-4ACF-86F8-4FA628F6A04A

P5875

Q33963958-3F4779C9-090A-4AFB-B5A2-186480EF2397

P698

Q33963958-334080AC-F83D-4CE7-8FA4-8577CC93F8B1

P921

Q33963958-6F7600EA-949B-4C9A-8D14-90738450D1BF

Q33963958-9565001C-DB1D-42AA-8C90-050535E98EA6

P932

Q33963958-034CA54B-6DF2-45A4-BEF8-2B08912F529E

P356

JOURNAL.PONE.0022204

P1433

P1476

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

@en

P2093

Airin Lam

http://www.w3.org/2001/XMLSchema#string

Alison K Starling

http://www.w3.org/2001/XMLSchema#string

Dana N Raugi

http://www.w3.org/2001/XMLSchema#string

Fatima Sall

http://www.w3.org/2001/XMLSchema#string

Fatou Traore

http://www.w3.org/2001/XMLSchema#string

James I Mullins

http://www.w3.org/2001/XMLSchema#string

Joshua Stern

http://www.w3.org/2001/XMLSchema#string

Kim G Wong

http://www.w3.org/2001/XMLSchema#string

Macoumba Toure

http://www.w3.org/2001/XMLSchema#string

Moon Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

Reduced rate of disease development after HIV-2 infection as compared to HIV-1

Slower heterosexual spread of HIV-2 than HIV-1.

Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic.

Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa.

HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in Senegal

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir

Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir

P304

e22204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0022204

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Geoffrey S. Gottlieb

P577

2011-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51499139

http://www.w3.org/2001/XMLSchema#string

P698

21765953

http://www.w3.org/2001/XMLSchema#string

P921

Afelika ya Lumonso

P932

3134476

http://www.w3.org/2001/XMLSchema#string